'Hypertension' and 'microalbuminuria': The bell tolls for thee

Kidney International

Volumn 69, Issue 1, 2006, Pages 22-28

  Forman, J P ^a,b,c   Brenner, B M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CHANNING LABORATORY   (United States)

Author keywords

Albuminuria; Blood pressure; Cardiovascular; Hypertension; Microalbminuria; Origins of disease

Indexed keywords

ALBUMIN; AMLODIPINE; ENALAPRIL; INDAPAMIDE; NISOLDIPINE; PERINDOPRIL; RAMIPRIL;

ALBUMINURIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; GENOTYPE; HISTORY; HUMAN; HUMAN GENOME; HYPERTENSION; HYPOALBUMINEMIA; HYPOTENSION; META ANALYSIS; MICROALBUMINURIA; NOMENCLATURE; NORMAL VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT SURVEY; SYSTEMATIC REVIEW;

EID: 30944468979     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000056     Document Type: Short Survey

References (70)

1. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA 1977; 237: 255-261.
2. The 1980 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1980; 140: 1280-1285.
3. The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1984; 144: 1045-1057.
4. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988; 148: 1023-1038.
5. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-183.
6. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
7. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
8. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 2004; 164: 2126-2134.
9. Viberti G, Pickup JC, Bilous RW et al. Correction of exercise-induced microalbuminuria in insulin-dependent diabetics after 3 weeks of subcutaneous insulin infusion. Diabetes 1981; 30: 818-823.
10. Viberti GC, Hill RD, Jarrett RJ et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1: 1430-1432.
11. Svendsen PA, Oxenboll B, Christiansen JS. Microalbuminuria in diabetic patients - a longitudinal study. Acta Endocrinol Suppl (Copenhagen) 1981; 242: 53-54.
12. Mathiesen ER, Ronn B, Jensen T et al. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 1990; 39: 245-249.
13. Morwood MJ, Brown P, Jatmiko et al. Further evidence for small-bodied hominins from the Late Pleistocene of Flores, Indonesia. Nature 2005; 437: 1012-1017.
14. Oliver WJ, Cohen EL, Neel JV. Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a 'no-salt' culture. Circulation 1975; 52: 146-151.
15. Lowenstein FM. A study of blood pressure and body measurements in medical students in the Brazilian Amazon City Belem. Cardiologia 1961; 39: 46-56.
16. Whyte HM, Yee IL. Serum cholesterol levels of Australians and natives of New Guinea from birth to adulthood. Australas Ann Med 1958; 7: 336-339.
17. Whyte HM, Graham IA, De Wolfe MS. Body fat, blood pressure and serum cholesterol of Australian men. Australas Ann Med 1958; 7: 328-335.
18. De Wolfe MS, Whyte HM. Serum cholesterol and lipoproteins in natives of New Guinea and Australians. Australas Ann Med 1958; 7: 47-54.
19. Whyte HM. Body fat and blood pressure of natives in New Guinea: reflections on essential hypertension. Australas Ann Med 1958; 7: 36-46.
20. Casley-Smith JR. Blood pressures in Australian aborigines. Med J Aust 1959; 46: 627-633.
21. Maddocks I. Blood pressures in Melanesians. Med J Aust 1967; 1: 1123-1126.
22. Fleming-Moran M, Santos RV, Coimbra Junior CE. Blood pressure levels of the Surui and Zoro Indians of the Brazilian Amazon: group- and sex-specific effects resulting from body composition, health status, and age. Hum Biol 1991; 63: 835-861.
23. Ghesquiere JL, Karvonen MJ. Some anthropometric and functional dimensions of the pygmy (Kivu Twa). Ann Hum Biol 1981; 8: 119-134.
24. Hollenberg NK, Martinez G, McCullough M et al. Aging, acculturation, salt intake, and hypertension in the Kuna of Panama. Hypertension 1997; 29: 171-176.
25. Diamond JM. Human evolution. Diabetes running wild. Nature 1992; 357: 362-363.
26. Sharma AM. The thrifty-genotype hypothesis and its implications for the study of complex genetic disorders in man. J Mol Med 1998; 76: 568-571.
27. James G, Baker P. Human Population Biology and Blood Pressure: Evolutional and Ecological Considerations and Interpretations of Population Studies, 2nd edn. Raven Press: New York, 1995.
28. Page LB. Epidemiologic evidence on the etiology of human hypertension and its possible prevention. Am Heart J 1976; 91: 527-534.
29. Hollenberg NK, Martinez G, McCullough M et al. Aging, acculturation, salt intake, and hypertension in the Kuna of Panama. Hypertension 1997; 29: 171-176.
30. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
31. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004; 24: e149-e161.
32. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423.
33. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
34. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
35. Rose G. Sick individuals and sick populations. Int J Epidemiol 2001; 30: 427-432 (discussion 433-424).
36. MacMahon S, Neal B, Rodgers A. Hypertension - time to move on. Lancet 2005; 365: 1108-1109.
37. Anderson TW. Re-examination of some of the Framingham blood-pressure data. Lancet 1978; 2: 1139-1141.
38. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979; 1: 861-865.
39. Untreated mild hypertension. A Report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet 1982; 1: 185-191.
40. Cooper SP, Hardy RJ, Labarthe DR et al. The relation between degree of blood pressure reduction and mortality among hypertensives in the Hypertension Detection and Follow-Up Program. Am J Epidemiol 1988; 127: 387-403.
41. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252.
42. Berl T, Hunsicker LG, Lewis JB et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 2005; 16: 2170-2179.
43. Kannel WB, Wilson PW, Nam BH et al. A likely explanation for the J-curve of blood pressure cardiovascular risk. Am J Cardiol 2004; 94: 380-384.
44. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
45. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097.
46. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2225.
47. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
48. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
49. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
50. Mehler PS, Coll JR, Estacio R et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003; 107: 753-756.
51. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
52. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
53. Svensson P, de Faire U, Sleight P et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001; 38: E28-E32.
54. Wright Jr JT, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
55. Ruggenenti P, Perna A, Loriga G et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365: 939-946.
56. Sarnak MJ, Greene T, Wang X et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142: 342-351.
57. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
58. Wachtell K, Ibsen H, Olsen MH et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901-906.
59. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
60. Kistorp C, Raymond I, Pedersen F et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616.
61. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32-35.
62. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46: 1-5.
63. Wang TJ, Evans JC, Meigs JB et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111: 1370-1376.
64. Arnlov J, Evans JC, Meigs JB et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-975.
65. Romundstad S, Holmen J, Kvenild K et al. Microalbuminuria and all-cause mortality in 2089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis 2003; 42: 466-473.
66. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 1994; 45: S145-S149.
67. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511-516.
68. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.
69. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.
70. Lea J, Greene T, Hebert L et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947-953.